Active Studies

This is a long-term study in cystic fibrosis patients who are participating in the Cystic
Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel
disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be
followed at their regular clinical care visits over a 10-year period and approached if they
develop symptoms of fibrosing colonopathy for collection and use of further detailed
information.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the
combination of INCB050465 and ruxolitinib in subjects with myelofibrosis.

This study consists of three portions: The first portion- Phase 1, or dose-escalation
portion, that will evaluate the safety and pharmacokinetic profile of venetoclax in
combination with low-dose cytarabine (LDC), define the maximum tolerated dose (MTD), and
generate data to support a recommended Phase 2 dose (RPTD) in treatment-naïve subjects with
Acute Myelogenous Leukemia (AML). Second portion, initial Phase 2 that will evaluate if the
RPTD has sufficient efficacy and acceptable toxicity to warrant further development of the
combination therapy. Subsequently, Phase 2 Cohort C, will evaluate the overall response rate
(ORR) for subjects allowed additional supportive medications (strong CYP3A inhibitors) if
medically indicated.

The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib
in women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian,
fallopian tube, or primary peritoneal cancer.

This is a multi-institutional, consortium-based, non-interventional prospective blinded
endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in
tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened
OS (primary outcome) and PFS (secondary outcome) times.

Pages